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The interferon-inducible myxovirus resistance (Mx)
proteins play important roles in combating a wide
range of virus infections. MxA inhibits many RNA
and DNA viruses, whereas the antiviral activity of
MxB is less well established. We find that human
MxB inhibits HIV-1 infection by reducing the level of
integrated viral DNA. Passaging HIV-1 through
MxB-expressing cells allowed the evolution of a
mutant virus that escapes MxB restriction. HIV-1
escapes MxB restriction by mutating the alanine
residue at position 88 in the viral capsid protein
(CA), with a consequent loss of CA interaction with
the host peptidylprolyl isomerase cyclophilin A
(CypA), suggesting a role for CypA inMxB restriction.
Consistent with this, MxB associates with CypA, and
shRNA-mediated CypA depletion or cyclosporine A
treatment resulted in the loss of MxB inhibition of
HIV-1. Taken together, we conclude that human
MxB protein inhibits HIV-1 DNA integration by a
CypA-dependent mechanism.
INTRODUCTION
The myxovirus resistance (Mx) genes were discovered for their
protection of mice from infection by influenza viruses (reviewed
in Haller and Kochs, 2011). It was observed in the 1960s that
wild mice were resistant to influenza viruses, whereas most
inbred mice were susceptible (Lindenmann, 1962). This trait
was later mapped to a locus on mouse chromosome 16 (Haller
et al., 1987; Reeves et al., 1988; Staeheli et al., 1988; 1986b).
The underlying gene products (named Mx) were first detected
in a two-dimensional electrophoresis of lysates from Mx+/+ and
Mx/ mouse cells that were treated with type I interferon
(Horisberger et al., 1983). Shortly after, cDNA of this gene was
cloned and named Mx1 (Staeheli et al., 1986a). The in vivo anti-
viral function of Mx1 was established by the increased survival of398 Cell Host & Microbe 14, 398–410, October 16, 2013 ª2013 ElsevMx1 transgenic mice upon virus challenge (Arnheiter et al., 1990;
Kolb et al., 1992).
Mice carry a second Mx gene named Mx2 that is positioned
together with Mx1 on chromosome 16 (Jin et al., 1999; Staeheli
and Sutcliffe, 1988). Both Mx1 and Mx2 bear antiviral activity
but inhibit distinct groups of viruses as a result of their different
subcellular localizations. Mx1 is a nuclear protein and restricts
influenza viruses and Thogoto virus, whereasMx2 is cytoplasmic
and inhibits vesicular stomatitis virus (VSV), La Crosse virus, and
Rift Valley fever virus (Haller and Kochs, 2011). Mx genes are
conserved in many vertebrates, including fish, birds, and mam-
mals (Haller et al., 2007). Their expression is inducible by type I
and type III interferons. Mx proteins are high-molecular-weight
guanosine triphosphatases (GTPases) and belong to the dyna-
min super family (Praefcke and McMahon, 2004).
Humans have two Mx genes, called MxA and MxB, which
reside on the long arm of chromosome 21 (Aebi et al., 1989).
The crystal structures of human MxA protein exhibit an
extended three-domain architecture in which the N-terminal
GTPase domain is connected to the C-terminal stalk via a
central bundle signaling element (BSE) (Gao et al., 2010;
2011). This protein structure implicates that multiple copies of
MxA protein are able to form a ring structure through intra-
and intermolecular interactions and that this ring structure cap-
tures viral capsid or other viral components (Gao et al., 2011). In
contrast to human MxA protein that inhibits a variety of viruses
(Haller and Kochs, 2011), MxB does not affect the viruses that
were tested (Pavlovic et al., 1990). It has thus been conceived
that human MxB may have lost its antiviral role during evolution.
Instead, MxB is solely involved in cellular activities, such as
regulating nuclear import (King et al., 2004; Mele´n et al.,
1996). This view is challenged by the results of two recent
studies that examined the antiviral property of hundreds of inter-
feron-stimulated genes (ISGs) (Liu et al., 2012; Schoggins et al.,
2011). In these studies, MxB was shown to reduce the infection
of VSV, mouse herpes virus type 68 (MHV-68), and to a lesser
degree, human immunodeficiency virus type 1 (HIV-1). In this
study, our results demonstrate that MxB strongly inhibits
HIV-1 infection by reducing the level of integrated viral DNA.
This anti-HIV-1 action can be overcome by a mutation in the
cyclophilin-binding loop in viral capsid.ier Inc.
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MxB Inhibits HIV-1 Infection
We first tested whether MxA and MxB affect HIV-1 replication.
To this end, we cloned MxA and MxB cDNA sequences into a
tetracycline-inducible retroviral vector expression system and
established a CD4+ T cell line called SupT1 that expressed
MxA or MxB under the induction by doxycycline (Dox) (Fig-
ure 1A). In the event that MxA or MxB does not inhibit HIV-1,
we wish to test whether this lack of inhibition results from the
inability to target HIV-1. We therefore generated the MxA-
CypA andMxB-CypA fusion proteins by attaching the cyclophilin
A (CypA) sequence to the C terminus of MxA or MxB (Figure 1A).
The specific binding of CypA to HIV-1 capsid is expected to
allow these two fusion proteins to inhibit HIV-1 infection as
reported for the TRIMCyp fusion proteins (Sayah et al., 2004;
Wilson et al., 2008).
Next, we challenged these SupT1 cell lines with anHIV-1 strain
called NL4-3 and monitored virus replication by measuring viral
reverse transcriptase activity in the culture supernatants at
various time intervals. Without Dox, HIV-1 replicated to compa-
rable levels in all cell lines that were tested (Figure 1B).When Dox
was added to induce Mx expression, MxB, but not MxA, pro-
foundly inhibited HIV-1 replication (Figure 1B). Both MxA-CypA
andMxB-CypA fusion proteins strongly suppressed HIV-1 infec-
tion (Figure 1B), suggesting that MxA is also able to inhibit HIV-1
when being targeted to viral capsid by CypA. We further
measured the effect of Mx and its CypA-fusion proteins on
HIV-1 infection using an HIV-1 reporter virus named NLENY1-
IRES (Levy et al., 2004). NLENY1-IRES has the yellow fluores-
cent protein (YFP) sequence inserted upstream of the HIV-1
nef gene, thus allowing the measurement of HIV-1 infection by
scoring YFP-positive cells. Consistent with HIV-1 replication
data shown in Figure 1B, MxA itself did not affect NLENY1-
IRES virus infection (Figure 1C). Both MxA-CypA and MxB-
CypA fusion proteins diminished the number of infected cells
by more than 90%; MxB led to a 50% inhibition (Figure 1C). In
order to rule out the possibility that the Flag tag may have modu-
lated the anti-HIV-1 activity of MxB, we expressed the untagged
version of MxB as well as the Flag-tagged MxB in SupT1 cells
and measured HIV-1 infection. Both versions of MxB diminished
HIV-1 infection to similar degrees (Figure S1 available online).
Together, these data suggest that MxB has the anti-HIV-1 activ-
ity and that this activity is greatly enhanced when MxB is directly
targeted to HIV-1 capsid by fusion with CypA.
MxB Reduces the Level of Integrated HIV-1 DNA
We next investigated which step of HIV-1 infection is affected by
MxB. We first monitored the early events of HIV-1 infection by
performing real-time PCR to quantify the products of HIV-1
reverse transcription as well as viral DNA integration in the in-
fected SupT1 cells. For each cell line, we calculated the ratios
of viral DNA amounts produced under Mx induction by Dox
versus those without Mx induction. These ratios are used to
determine the effects of Mx and their fusion proteins on viral
DNA synthesis. Results showed that the level of integrated
HIV-1 DNA, but not that of the early or late reverse transcription
products, was reduced by MxA-CypA, MxB-CypA, and MxB
itself (Figure 2A). We also measured the level of viral 2-long ter-Cell Hostminal repeat (LTR) circle DNA that is only formed within the
nucleus and has thus been utilized as a marker to evaluate the
nuclear entry of HIV-1 DNA (Bukrinsky et al., 1992). No significant
change in this regard was caused by either Mx or their fusion
proteins (Figure 2A). These results suggest that MxB impairs
the integration of HIV-1 DNA.
We next asked whether MxB affects the steps of HIV-1 repli-
cation after DNA integration. To answer this question, human
embryonic kidney (HEK) 293T cells were cotransfected with
HIV-1 DNA and Mx or their fusion protein DNA clones. Similar
levels of viral Gag protein were detected in cells that expressed
Mx or their fusion proteins (Figure 2B).When the amounts of virus
particles in the culture supernatants were determined by
measuring the levels of viral reverse transcriptase activity, a
moderate reduction was seen for the two fusion proteins, but
no decrease for MxB (Figure 2C). Interestingly, when we
assessed the amounts of infectious HIV-1 particles by infecting
the TZM-bl indicator cells, we observed a 10-fold reduction
associated with MxA-CypA and MxB-CypA expression, but no
significant effect by MxB (Figure 2C). We suspected that the
deleterious effects of MxA-CypA andMxB-CypA on HIV-1 infec-
tivity may result from their incorporation into HIV-1 particles due
to the binding of CypA to viral capsid protein. Indeed, both MxA-
CypA and MxB-CypA were detected in HIV-1 particles (Fig-
ure 2D). Surprisingly, MxB itself was also seen in the purified
viruses (Figure 2D). MxB appeared to become packaged into
HIV-1 particles by a CypA-independent mechanism, since the
association of CypA and MxA-CypA, but not MxB and MxB-
CypA, with HIV-1 particles was blocked by cyclosporine A
(CSA), a drug that obstructs the interaction of HIV-1 capsid
and CypA (Figure 2D). We suspect that the observed association
of MxB with HIV-1 virions is either a result of its interaction with
viral proteins or its ability to bind to membranes (Haller and
Kochs, 2011). Together, these data suggest that MxB itself
affects neither HIV-1 protein expression nor virus production.
Knockdown of MxB Alleviates Interferon-Induced
Inhibition of HIV-1 Infection
We next investigated whether MxB, as an interferon-induced
protein, contributes to the suppression of HIV-1 infection by
interferon. We first generated two stable SupT1 cell lines that
were transducedwithMxB shRNA named shMxB1 and shMxB2.
Without interferon treatment, very low levels of MxB could be
detected in the control and the shMxB1 and shMxB2 cells (Fig-
ure 3A). Treatment with interferon a2b (IFNa2b) markedly
increased MxB level in the control SupT1 cells, but the increase
was much less pronounced in the shMxB1 and shMxB2 cells,
which indicates an effective knockdown of MxB (Figure 3A).
We next infected these SupT1 cells with HIV-1 and scored the
viral p24-positive cells by flow cytometry. A 4-fold inhibition of
HIV-1 infection by IFNa2b was observed in control SupT1 cells
(Figures 3B and 3C). Knockdown of MxB with shMxB1 and
shMxB2 significantly attenuated this inhibition by IFNa2b, with
shMxB1 restoring the infection almost to the control level due
to a very efficient depletion of MxB (Figures 3B and 3C). We
then performed the same experiments in U87-MG cells, a
human astroglioma cell line. Again, the shMxB1 clone efficiently
depleted the endogenousMxB that was induced by IFNa2b (Fig-
ure 3D). A more than 60-fold reduction of HIV-1 infection was& Microbe 14, 398–410, October 16, 2013 ª2013 Elsevier Inc. 399
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Figure 1. Effects of MxA, MxB, and Their CypA Fusion Proteins on HIV-1 Replication
(A) The domain structures of MxA, MxB, and their CypA fusion proteins are illustrated. G, GTPase domain; B, central bundle signal element; Stalk, stalk domain.
Expression of Mx and their fusion proteins in the stably transduced SupT1 cell lines was examined by western blotting. All five proteins contain the Flag-tag
sequence at their C termini.
(B) Replication of HIV-1NL4-3 in SupT1 cell lines with or without the expression of CypA, MxA, MxA-CypA, MxB, or MxB-CypA. Amounts of viruses in the culture
supernatants were determined by measuring levels of viral reverse transcriptase activity at different time intervals. Results shown represent one of three
independent infection experiments.
(C) One-round infection of NLENY1-IRES virus in the control SupT1 cells and cells expressing Mx or Mx-CypA fusion proteins. At 40 hr after infection, YFP-
positive cells were scored by flow cytometry. Results from one representative experiment are shown. Data of three independent infections are summarized in the
bar graph. Data are represented as mean ± SEM. See also Figure S1.
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Figure 2. MxB Diminishes the Level of Inte-
grated HIV-1 DNA
(A) Effects of Mx and Mx-CypA fusion proteins on
HIV-1 reverse transcription and integration. HIV-
1NL4-3 was used to infect SupT1 cell lines with or
without induction of Mx or Mx-CypA. Amounts of
early and late reverse transcription DNA products,
as well as 2-LTR circle DNA, were determined by
real-time quantitative PCR. Levels of integrated
viral DNA were measured by Alu-PCR. Effects of
Mx or Mx-CypA proteins on HIV-1 DNA production
were determined by calculating the ratios of viral
DNA amounts produced under Dox induction
versus that without Dox induction. Data are rep-
resented as mean ± SEM.
(B) Effects of Mx and Mx-CypA proteins on HIV-1
Gag expression. HEK 293T cells were co-
transfected with HIV-1NL4-3 DNA together with Mx
or Mx-CypA plasmid DNA. Levels of Mx, Mx-
CypA, and viral Gag proteins were examined by
western blotting. Tubulin was probed as the
internal control.
(C) Effects of Mx and Mx-CypA on virus produc-
tion. Amounts of HIV-1 particles in the superna-
tants were determined either by measuring levels
of viral reverse transcriptase activity (representing
total amounts of viruses) or by infecting the TZM-
bl indicator cells (representing the levels of infec-
tious virus particles). Data are represented as
mean ± SEM.
(D) Incorporation of Mx and Mx-CypA into HIV-1
particles. HEK 293T cells were transfected as
described above with or without cyclosporine A
(CSA) treatment. The progeny virions were har-
vested by ultracentrifugation and probed for the
presence of Mx and Mx-CypA proteins in western
blotting.
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MxB Inhibits HIV-1observedwith IFNa2b treatment (Figures 3E and 3F). This drastic
suppression was largely alleviated with depletion of IFNa2b-
induced MxB by shMxB1 (Figures 3E and 3F). We therefore
conclude that MxB is the major player behind IFNa2b-mediated
inhibition of HIV-1 infection.
HIV-1 Mutates Capsid Protein to Escape from MxB
Restriction
We next tried to determine which viral protein is the target of
MxB. To answer this question, we performed virus evolution
experiments to identify and characterize MxB-resistant viruses.
After five passages in MxB-expressing SupT1 cells, HIV-1 re-
gained its replication capacity. Sequencing the entire genomes
of the viruses at each passage revealed three mutations,
CA88, Vpu(), and Env539, among which Env539 emerged at
the second passage, whereas the other two mutations were
detected at passage 5 (Figure 4A). None of the three mutations
were detected in HIV-1, which had replicated in the controlCell Host & Microbe 14, 398–410,SupT1 cells for the same number of
passages. The CA88 mutation changes
the capsid residue A88, which is one of
the key amino acids for CypA binding
(Figure 4B) (Gamble et al., 1996; Luban
et al., 1993). The Vpu() mutation
changes the translation initiation codon ATG to ATA and thus
eliminates Vpu expression. Env539 changes the A539 residue
in gp41 to valine, which is located in the first heptad repeat
(HR1) (Figure 4B).
In order to determine which of these three mutations rescue
HIV-1 from MxB inhibition, we inserted these three mutations
either individually or in different combinations into HIV-1 proviral
DNA and generated seven recombinant DNA clones. We then
transfected the wild-type and the mutated viral DNA into HEK
293T cells to produce virus particles. Western blotting analysis
showed that the Vpu() mutation eliminated Vpu expression,
but the Env539 mutation did not evidently affect the expression
of viral Env protein (Figure 4C). The CA88 mutation significantly
diminished the level of CypA in HIV-1 particles (Figure 4D). We
next used the same amounts of the wild-type and mutated
viruses to infect the MxB-expressing SupT1 cells. The amounts
of infectious virus particles made were determined by infecting
the TZM-bl indicator cells. Without MxB induction (in theOctober 16, 2013 ª2013 Elsevier Inc. 401
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Figure 3. Effect of MxB Knockdown on Interferon Inhibition of HIV-1 Infection
(A) Stable MxB-knockdown in SupT1 cells. Levels of endogenous MxB with or without IFNa2b treatment were examined by western blotting.
(B andC) HIV-1 infection of the control andMxB-knockdown SupT1 cells with or without IFNa2b. The infected cells were stainedwith anti-HIV-1 p24 antibody and
scored by flow cytometry. (B) Results from one representative infection are shown. (C) Results of three independent infections are summarized in the bar graph.
(D) Knockdown of MxB in U87-MG cells by transfection of shMxB DNA clones. Levels of endogenous MxB with or without IFNa2b treatment were determined by
western blotting.
(E) HIV-1 infection of U87-MG cells was determined by scoring p24-positive cells.
(F) The bar graph presents the average data from three independent infections. Data are represented as mean ± SEM.
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Figure 4. Identification of Escape Mutations in MxB-Resistant HIV-1
(A) Illustration of mutations in the genome of MxB-resistant HIV-1. Mutations CA88 and Env539 are located in capsid and Env, respectively. The Vpu()
mutation changes the translation start codon ATG of Vpu to ATA. The presence of the CA88, Vpu(), and Env539 mutations at each of the four virus passages is
also shown.
(B) Depiction of the CA88 mutation in the CypA-binding loop in HIV-1 capsid. Location of the Env539 mutation in the N-heptad repeat in gp41 is also highlighted.
The models were generated using the I-TASSER server for protein three-dimensional (3D) structure prediction (Zhang, 2008).
(C) Effects of the escapemutations on the expression of viral Env, Gag, and Vpu proteins. The CA88, Vpu(), and Env539mutations were inserted into HIV-1 DNA
either individually or in different combinations. The wild-type (NL4-3) and mutated HIV-1 DNA clones were transfected into HEK 293T cells. Expression of HIV-1
proteins was examined by western blotting.
(D) Incorporation of CypA into the wild-type and mutated HIV-1 particles. The same p24 amounts of HIV-1 particles were probed in western blots with anti-CypA
antibody. Amounts of CypA in transfected HEK 293T cells were also determined by western blotting. The CA89 mutant is defective in CypA binding and is
included as a control.
Cell Host & Microbe
MxB Inhibits HIV-1absence of Dox), as compared to thewild-type HIV-1(NL4-3), the
CA88 mutant produced 6-fold less infectious viruses, whereas
the Env539 mutant generated 7-fold more viruses, and the
Vpu() mutant showed a moderate 2-fold increase (Figure 5A).
This defect in virus production associated with CA88 was cor-
rected by the Env539 mutation, since both the CA88/Env539
and the CA88/Vpu()/Env539 mutants generated wild-type
levels of infectious viruses (Figure 5A). The Vpu() mutation
alone did not compensate for CA88 in this regard, given the
similar low levels of virus production between the CA88 and
the CA88/Vpu() mutants (Figure 5A). When MxB expression
was induced by Dox, the yield of wild-type HIV-1(NL4-3) was
diminished by 8-fold (Figures 5A and 5B). A similar extent ofCell Hostreduction was observed for the mutants Vpu(), Env539, and
Vpu()/Env539, but not for CA88, CA88/Vpu(), CA88/Env539,
or CA88/Vpu(-)/Env539 that contain the CA88 mutation (Figures
5A and 5B). This result suggests a specific role of the CA88
mutation in overcoming MxB restriction.
We then monitored the growth of these viruses in MxB-
expressing SupT1 cells over a period of 20 days. MxB expres-
sion inhibited the replication of wild-type HIV-1(NL4-3), Vpu(),
Env539, and Vpu()/Env539, but not that of CA88, CA88/
Vpu(), CA88/Env539, or CA88/Vpu()/Env539 (Figure 5C).
SinceMxB reduces the level of integrated HIV-1 DNA (Figure 2A),
we further tested whether the CA88 mutation rescues HIV-1
infection by correcting this defect. Indeed, MxB reduced the& Microbe 14, 398–410, October 16, 2013 ª2013 Elsevier Inc. 403
103
104
105
106
107
4 6 8 10 12 14 16 18 20 22
103
104
105
106
107
103
104
105
106
107
103
104
105
106
107
4 6 8 10 12 14 16 18 20 22
Vi
ra
l R
T 
ac
tiv
ity
 (c
pm
)
Days after infection
NL4-3
CA88
Vpu(-)
Env539
CA88/Vpu(-)
CA88/Env539
Vpu(-)/Env539
CA88/Vpu(-)/Env539
-Dox +Dox
NL4-3
CA88
Vpu(-)
Env539
CA88/Vpu(-)
CA88/Env539
Vpu(-)/Env539
CA88/Vpu(-)/Env539R
el
at
iv
e 
vi
ru
s 
in
fe
ct
io
n 
(R
LU
)
105
106
107
108
109
-Dox +Dox
0
2
4
6
8
10
Fo
ld
 o
f i
nh
ib
iti
on
 b
y 
M
xB NL4-3
CA88
Vpu(-)
Env539
CA88/Vpu(-)
CA88/Env539
Vpu(-)/Env539
CA88/Vpu(-)/Env539
A
B
C
D
N
L4-3
C
A
88
V
pu(-)
E
nv539
C
A
88/V
pu(-)
C
A
88/E
nv539
V
pu(-)/E
nv539
C
A
88/V
pu(-)/E
nv539
0
Vi
ra
l D
N
A 
pr
od
uc
tio
n 
(+
D
ox
/-D
ox
)
0.5
1.0
1.5
2.0
2.5
3.0
Early viral DNA
Late viral DNA
Integrated viral DNA
2-LTR DNA
Figure 5. The CA88 Mutation Confers Resistance to MxB Restriction
(A) Infection of SupT1 cells with the wild-type (NL4-3) and mutated HIV-1 with or without MxB induction by Dox. The amounts of infectious HIV-1 particles in the
supernatants from the infected SupT1 cells were determined by infecting the TZM-bl indicator cells. Results shown are the levels of luciferase activity in the
infected TZM-bl cells.
(B) Folds of inhibition of the wild-type and mutated HIV-1 by MxB were calculated by dividing the amounts of HIV-1 (represented by the luciferase values in A)
made without MxB expression by those made under MxB expression. Results shown are the averages of three independent experiments.
(C) Replication of the wild-type and mutated HIV-1 in SupT1 cells with or without MxB induction by Dox. Results of one representative infection experiment are
shown.
(D) Effects of MxB on reverse transcription and integration of the wild-type and mutated viruses. Each bar represents the ratio of viral DNA amount produced
under MxB induction by Dox versus that made without MxB induction. Results shown are the average of three independent infection experiments. Data are
represented as mean ± SEM.
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MxB Inhibits HIV-1integrated viral DNA levels for those viruses that did not carry the
CA88 mutation and exerted no effect on viruses carrying CA88
(Figure 5D). A further examination of 2-LTR DNA production
showed a 2-fold increase only for CA88-containing viruses in
the context of MxB expression (Figure 5D), which suggests
that the CA88mutation overcomesMxB restriction by increasing
the nuclear entry of viral DNA.404 Cell Host & Microbe 14, 398–410, October 16, 2013 ª2013 ElsevCypA Is Required for MxB to Inhibit HIV-1
Since the CA88 mutation occurs in the CypA-binding site in
viral capsid, its rescue effect suggests a possible involvement
of CypA in MxB restriction. To test this, we first utilized CSA
to block the interactions of CypA with HIV-1 capsid and evalu-
ated the anti-HIV-1 activity of MxB. In the context of control
SupT1 cells without MxB expression, CSA diminished HIV-1ier Inc.
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Figure 6. Cyclosporine A Abrogates MxB
Inhibition of HIV-1 Infection
(A and B) HIV-1 was used to infect SupT1 cells with
or without induction of MxB by Dox. The CA88 and
CA89 mutants are defective in binding to CypA.
One group of cells was treated with CSA prior to
infection. The p24-positive cells were scored by
flow cytometry. The results of one representative
infection is shown in (A). Results of three indepen-
dent infections are summarized in (B). The infection
of control SupT1 cells by HIV-1NL4-3 is arbitrarily set
as 1. Data are represented as mean ± SEM. See
also Figure S2.
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MxB Inhibits HIV-1infection by 2.3-fold (Figures 6A and 6B). Expression of MxB
alone led to a 3.6-fold reduction of HIV-1 infection, as measured
by scoring p24-positive cells (Figures 6A and 6B). When CSA
was added to MxB-expressing SupT1 cells, HIV-1 infection
was rescued to 80% of that in the control SupT1 cells (Figures
6A and 6B). This result suggests not only that CSA overcomes
the anti-HIV-1 activity of MxB, but also that MxB expression
offsets the majority of the adverse effect of CSA on HIV-1
infection.
We then performed the same experiments with two HIV-1
mutants, CA88 and CA89, which are both defective in CypA-
binding (Gamble et al., 1996). As expected, both mutants were
much less infectious than the wild-type HIV-1(NL4-3) (Figures
6A and 6B). Interestingly, a modest increase in the infection of
CA88 and CA89 was observed in MxB-expressing SupT1 cells
(Figures 6A and 6B). It remains to be tested whether these two
mutants respond to MxA in a similar fashion. In further support
of the necessity of CypA in the MxB restriction, two lentiviruses,
HIV-2(Rod) and SIVmac239, that bear capsids devoid of CypA
binding (Lin and Emerman, 2006) were marginally affected by
MxB (Figure S2). A CSA-resistant HIV-1 mutant A92E is still sus-
ceptible to MxB restriction since the A92E mutant capsid bindsCell Host & Microbe 14, 398–410to CypA, as does the wild-type capsid
(Figure S2) (Aberham et al., 1996; Braaten
et al., 1996).
Finally, we knocked down CypA with
shRNA in SupT1 cells (Figure 7A) and
measured how the anti-HIV-1 activity of
MxB was affected. The shCypA1 clone
reduced endogenous CypA much more
efficiently than shCypA2. Concomitantly,
shCypA1 elevated HIV-1(NL4-3) infection
in MxB-expressing cells close to 80% of
that in cells without MxB expression (Fig-
ures 7B and 7C).
This dependence on CypA suggests an
association of MxB with CypA and/or a
requirement of CypA for MxB to recognize
HIV-1 capsid. In support of the first possi-
bility, the endogenous MxB was coimmu-
noprecipitated with CypA (Figure S3).
Interestingly, this association was disrup-
ted by CSA (Figure S3), suggesting that
MxB may bind to the catalytic site ofCypA, similar to the binding of CypA to HIV-1 capsid (Gamble
et al., 1996). No interaction of CypA with MxA was detected (Fig-
ure S3). An interaction ofMxBwith Gag or themature capsid was
not detected in the coimmunoprecipitation (coIP) experiments
that were performed with either cell lysates or virus particles
that were solubilized with detergents (data not shown). Since
HIV-1 core is disrupted by detergents in the coIP experiments,
it remains to be examined whether MxB recognizes the high-
order conformation of viral capsid that is formed with the
assistance of CypA.
DISCUSSION
Results of our study suggest that MxB inhibits HIV-1 infection by
reducing viral DNA integration. This mechanism of targeting
HIV-1 DNA replication mirrors the antiviral action by MxA that
recognizes the viral nucleocapsid, such as that of the influenza
virus, and impairs viral genome replication (Gao et al., 2011; Zim-
mermann et al., 2011). It is conceivable that both MxA and MxB
may have evolved to recognize different viruses and, in the
meantime, preserved the same antiviral mechanism of targeting
viral genome replication complex. In support of this speculation,, October 16, 2013 ª2013 Elsevier Inc. 405
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Figure 7. Knockdown of CypAOvercomes Inhibition of HIV-1 byMxB
(A) The MxB-transduced SupT1 cells were infected with retrovirus particles
expressing shRNA targeting CypA. Levels of endogenous CypA and the
expression of MxB were determined by western blotting.
(B) These shRNA-treated SupT1 cells were infected by HIV-1 with or without
MxB induction by Dox. HIV-1-infected cells were detected by staining for viral
p24 and scored by flow cytometry.
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406 Cell Host & Microbe 14, 398–410, October 16, 2013 ª2013 ElsevMxB shares similar domain organization with MxA (Figure S4A).
Results of computer modeling further revealed that, similar to
MxA, MxB also folds into a globular GTPase head, a BSE hinge,
and a stalk domain (Figure S4B). The similar architectures ofMxA
and MxB suggest a common molecular mechanism behind their
antiviral actions. Their different abilities to inhibit HIV-1 may
result from the incompetence of MxA in recognition of HIV-1. It
is known that the antiviral specificity of MxA is determined by a
loop structure called Loop4 (Gao et al., 2010). On the basis of
sequence homology and computer modeling, we were able to
identify this putative loop in MxB (Figure S4C). Sequence align-
ment shows significant difference in the Loop4 sequences
between MxA and MxB (Figure S4C), which may underlie their
different antiviral specificities. MxB also exhibits GTPase activity
(Mele´n et al., 1996). Given the importance of this activity for the
antiviral function of MxA (Pitossi et al., 1993; Ponten et al., 1997),
it would be interesting to determine whether MxB also needs
GTP binding and hydrolysis to inhibit HIV-1.
MxB reduces the levels of integrated HIV-1 DNA, whereas it
does not affect viral 2-LTR circles. Since HIV-1 2-LTR circles
are only present in nuclei, and thus have been regarded as a
marker of nuclear entry of viral DNA (Bukrinsky et al., 1992), it
is concluded that MxB impairs the integration step and spares
the nuclear entry of viral DNA. MxB exhibits different subcellular
distribution in different cell types with a dominant nuclear local-
ization in lymphocytes and macrophages (Aebi et al., 1989; King
et al., 2004; Mele´n et al., 1996; Pavlovic et al., 1990). We have
observed a major residence of endogenous MxB at the perinu-
clear region in HeLa cells (Figure S5). The presence of MxB in
the nucleus may have provided the opportunity to interfere
with HIV-1 DNA integration. In contrast, MxA has been seen
only in the cytoplasm (Haller and Kochs, 2011).
Results of our studies suggest that MxB inhibition of HIV-1 is
CypA dependent. CypA also assists Trim5a of rhesus monkeys
to inhibit HIV-1 in Old World primate cells (Berthoux et al.,
2005; Keckesova et al., 2006; Lin and Emerman, 2008; Stremlau
et al., 2006b), especially so in nondividing cells (Qi et al., 2008;
Yamashita and Emerman, 2009). Notably, although Trim5a of
rhesus monkeys abrogates HIV-1 viral reverse transcription by
promoting HIV-1 core disassembly (Kutluay et al., 2013; Perez-
Caballero et al., 2005; Stremlau et al., 2006a; Wu et al., 2006),
its CypA-dependent inhibition activity in nondividing cells
appears to take place after reverse transcription (Yamashita
and Emerman, 2009), which is similar to the CypA-dependent
impediment of HIV-1 integration by MxB.
It is intriguing that CSA not only overcomes MxB restriction,
but also stimulates HIV-1 infection of the MxB-expressing cells
(Figure 6). Similarly, MxB moderately increases the infection of
A88T and G89V viruses (Figure 6). It appears that MxB is able
to exert two different effects on HIV-1 infection: an inhibitory
effect under the condition of CypA interaction with viral capsid
and a stimulatory effect in the absence of CypA-capsid interac-
tion. It should be noted that these two seemingly controversial
activities occur under two mutually exclusive conditions. In
the context of HIV-1 infection of natural target cells, such as(C) Averages of three independent experiments are shown in the bar graph,
with the infection of control SupT1 cells by HIV-1NL4-3 arbitrarily set as 1. Data
are represented as mean ± SEM. See also Figure S3.
ier Inc.
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MxB Inhibits HIV-1CD4+ T cells (e.g., SupT1) and macrophages (e.g., U87-MG),
that express CypA, MxB acts as a restriction factor. This dual-
function phenomenon may be a result of the different properties
of the two forms of MxB that are naturally expressed in cells
(Mele´n et al., 1996). The full-length MxB is expressed as a
78 kDa form and resides within the nucleus. The 76 kDa version
is short of the first 25 amino acids and is cytoplasmic.
Our results do not exclude the possibility that MxB acts by
interfering with the function of CypA in HIV-1 infection. CypA
was reported to stabilize HIV-1 core and, in concert with other
cellular proteins (such as TNPO3) that promote HIV-1 core disas-
sembly, regulate HIV-1 uncoating (Shah et al., 2013). One
outcome of disrupting the function of CypA is the alteration of
HIV-1 integration targeting preference and, as a result, the
reduction of HIV-1 replication (Schaller et al., 2011). It will be
interesting to test whether, when being induced by interferon,
MxB also affects the selection of HIV-1 DNA integration sites,
which may lead to the severe defect in virus production as
observed in this study.
Our study enlists MxB as a cellular factor that inhibits the early
steps of HIV-1 infection. Among the capsid-targeting restriction
factors, a truncated version of CPSF6 (cleavage and polyadeny-
lation specific factor 6), CPSF6-358, inhibits nuclear import of
HIV-1 preintegration complex (PIC) (Lee et al., 2010). Results
of X-ray crystallography revealed an interface at the N-terminal
domain of capsid that serves as the binding surface for CPSF6
(Price et al., 2012). Mutating this interface on capsid alters the
dependence of HIV-1 PIC nuclear import on the NUP358-
TNPO3 pathway (Price et al., 2012). Given that NUP358 contains
a cyclophilin domain that interacts with HIV-1 capsid (Schaller
et al., 2011), MxB may compete with viral capsid for binding to
this cyclophilin domain in NUP358 and alter HIV-1 utilization of
the NUP358-TNPO3 pathway for nuclear entry.
The anti-HIV-1 activity of MxB is greatly enhanced when being
attached by CypA. This enhancement is likely a result of the
efficient targeting of MxB to HIV-1 capsid by CypA. Equally
possible is that multimerization of MxBmay promote the binding
of CypA to HIV-1 capsid and hence change CypA from an acti-
vator to an inhibitor (Javanbakht et al., 2007). In any event, our
study recommends MxB as one of the few cellular proteins,
including Trim5a, Trim21, and Fv1 (Friend virus susceptibility
protein 1), that can block HIV-1 infection when being appended
by CypA (Brennan et al., 2008; Chan et al., 2012; Newman et al.,
2008; Sayah et al., 2004; Schaller et al., 2007; Virgen et al., 2008;
Wilson et al., 2008). A combination of these different restriction
factors, through the use of CypA as the targeting tool, may
lead to the development of effective gene therapy strategies to
block HIV-1 infection. These examples of CypA-based antivirals
allude to the possible existence in human genome of HIV-1
restriction factors containing the cyclophilin domain.
EXPERIMENTAL PROCEDURES
Plasmid DNA and Reagents
The Retro-X Tet-On and Retro-X-Pur DNA vectors were purchased from
Clontech Laboratories, and human MxA (MGC-44833), MxB (MGC-34215),
and CypA (MGC-2351) cDNA clones from the ATCC. The MxA, MxB, and
CypA cDNA sequences were inserted between the BamHI and NotI sites of
Retro-X-Pur to generate Retro-X-MxA, Retro-X-MxB, and Retro-X-CypA.
The CypA sequence was attached to the C termini of MxA or MxB, and theCell Hostin-frame fusion protein coding sequences were inserted between the BamHI
and the MulI sites of Retro-X-Pur. For detection by western blotting, the
Flag-tag sequence was attached to the C termini of the above proteins. We
also cloned the untagged version of MxB and the Flag-tagged MxB into the
pQCXIP expression vector (Clontech). The infectious viral DNA clones HIV-
1(NL4-3), HIV-2(Rod), and SIVmac239 were obtained from the NIH AIDS
Research and Reference Reagent Program. The NLENY1-IRES viral DNA
was kindly provided by Dr. David Levy (Levy et al., 2004). The CA88 (A88 to
T88), CA89 (G89 to V89), A92E, and Env539 (A539 to V539) point mutations
were generated in the context of the NL4-3 viral DNA using the Site-Directed
Mutagenesis Kit (Agilent Technologies).
The anti-Flag and anti-tubulin antibodies were purchased fromSigma, FITC-
conjugated anti-HIV-1 p24 antibody from Beckman Coulter, and anti-CypA
antibody from Sigma. Puromycin and doxycycline were purchased from
Sigma, and G418 was purchased from Invitrogen.
Cell Culture and Transfection
The HEK 293T cells, GP2-293 cells, TZM-bl cells, and U87-MG cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (Invitrogen). GP2-293 cells are a packaging cell line
that produces retrovirus particles for transduction experiments (Clontech).
TZM-bl is an HIV indicator cell line that measures the level of infectious
HIV-1 particles (Wei et al., 2002). U87-MG are human astroglioma cells (NIH
AIDS Research and Reference Reagent Program). SupT1 cells were grown
in RPMI1640 medium supplemented with 10% fetal bovine serum (Invitrogen).
Transfection of HEK 293T, GP2-293, or U87-MG cells was performed with
Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer’s
instructions.
Generation of Stably Transduced Cell Lines
We first prepared retrovirus particles that packaged the following vector RNA:
Retro-X Tet-On, Retro-X-Pur, Retro-X-MxA, Retro-X-MxB, Retro-X-CypA,
Retro-X-MxA-CypA, and Retro-X-MxB-CypA. This was conducted by trans-
fecting the vector DNA into the GP2-293 packaging cells (Clontech), followed
by collecting the virus particles in the culture supernatants. The Retro-X Tet-
On virus particles were first used to infect SupT1 cells. The stably transduced
cells were selected with G418 (1 mg/ml). The G418-resistant cells were then
infected with viruses that packaged RNA from the vectors of Retro-X-MxA,
Retro-X-MxB, Retro-X-CypA, Retro-X-MxA-CypA, and Retro-X-MxB-CypA.
Following selection with puromycin (2 mg/ml), the stably transduced cells
were characterized by western blotting to measure the expression of Mx
proteins with induction by Dox (0.5 mg/ml).
Virus Infection
HIV-1 stock was prepared by transfecting the HEK 293T cell with HIV-1NL4-3
DNA clone. The amount of HIV-1 was determined by HIV-1 p24/CA ELISA.
Viruses equivalent to 5 ng of viral p24 were used to infect SupT1 cells.
Virus growth was monitored by measuring viral reverse transcriptase activity
in the culture supernatants at different time intervals. For a short-term
infection, SupT1 cells were exposed to HIV-1 equivalent to 150 ng of viral
p24 for 4 hr before the virus inoculants were washed off. After an additional
40 hr, the amount of viruses that were released into the culture supernatant
was determined either by measuring viral reverse transcriptase activity or by
infecting the TZM-bl indicator cells. The number of infected SupT1 cells was
determined by flow cytometry after staining with FITC-conjugated anti-
p24(CA) antibody. HIV-2(Rod) and SIVmac239 viruses were produced by
transfecting HEK 293T cells. A plasmid DNA expressing VSV-G protein was
also used in transfection so that the viruses made could infect SupT1 cells
that lack the expression of CCR5. Viruses with the same quantities of viral
reverse transcriptase activity were used to infect SupT1 cells. The amounts
of infectious viruses thus produced were determined by infecting the TZM-bl
indicator cells.
Knockdown of CypA and MxB
We purchased the shRNA DNA clones that target CypA (shCypA1,
TRCN0000049228; shCypA2, TRCN0000049229) and MxB (shMxB1,
TRCN0000056713; shMxB2, TRCN0000056715) from Sigma. The control
shRNA contains the scrambled target sequence (Sigma). The shRNA DNA& Microbe 14, 398–410, October 16, 2013 ª2013 Elsevier Inc. 407
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MxB Inhibits HIV-1clones were transfected into HEK 293T cells together with plasmid DNA
pLP1 (encoding Gag and Gag-Pol), pLP2 (encoding Rev), and pVSV-G
(encoding the glycoprotein of VSV). The virus particles thus made were
used to infect SupT1 cells to knock down the target gene. Stably transduced
cells were selected with puromycin (2 mg/ml). MxB was transiently knocked
down in U87-MG cells by direct transfection of the shMXB1 or shMxB2 DNA
clones.
MxB Antibody Production
The MxB DNA sequence encoding the amino acid fragment 167–271 was
cloned into the pGEX4T-1 vector to express the GST-MxB(167–271) fusion
protein in bacteria, followed by purification using the glutathione Sepharose
beads (GE Healthcare) in accordance with the manufacturer’s instructions.
The purified GST-MxB(167–271) protein was used to immunize rabbits to
produce anti-MxB polyclonal antibodies (MediMabs).
Western Blotting and Immunoprecipitation
Cells were first lysed on ice for 15 min. Cell debris was cleared by centrifuging
in a bench-top eppendorf centrifuge at 13,000 rpm for 5 min. A total of 20 mg of
cell extracts from each sample was subject to electrophoresis in SDS-PAGE.
Proteins were then transferred onto the polyvinylidene difluoride (PVDF) mem-
branes (Roche) and probed with antibodies. For immunoprecipitation, cell
lysates were incubated with anti-Flag M2 affinity gel (Sigma) overnight at
4C, followed by washing with the lysis buffer containing 20 mM Tris-HCl
(pH 7.5), 150mMNaCl, 5 mMEDTA, and 1% Triton X-100. The bound proteins
were eluted with 33 FLAG peptide solution (Sigma) and examined by western
blotting with antibodies against Flag or MxB.
Measuring Viral cDNA Synthesis
Levels of early and late viral reverse transcription products, as well as the
levels of integrated viral DNA, were measured by real-time PCR as we
previously described (Lu et al., 2011). Briefly, SupT1 cells were infected with
HIV-1 (equivalent to 150 ng viral p24) for 16 hr followed by the extraction of
total cellular DNA using the DNeasy Tissue Kit (QIAGEN). Nevirapine (1 mg/
ml) was used to block reverse transcription, and the results served as
controls for PCR. Equal amounts of extracted cellular DNA were subject to
the following PCR. The early viral DNA products were amplified with
primer pair 50-TTAGACCAGATCTGAGCCTGGGAG-30/50-GGGTCTGAGG
GATCTCTAGTTACC-30, and the late viral DNA products were amplified
with primer pair 50-TGTGTGCCCGTCTGTTGTG-30/50-GAGTCCTGCGTC
GAGA-30 (Li et al., 2007). The integrated viral DNA was first amplified
with primer pair 50-GCCTCCCAAAGTGCTGGGATTACAG-30/50-GTTCCTG
CTATGTCAC TTCC-30, which binds to Alu and HIV-1 Gag DNA sequences,
followed by a second-round of PCR with primers 50-TTAAGCCTCAAT
AAAGCTTGCC-30/50-GTTCGGGCGCCACTGCTAGA-30, which bind to HIV-1
long terminal repeat (Yu et al., 2008). The HIV-1 2-LTR DNA was amplified
with primer pair 50-CCCTCAGACCCTTTTAGTCAGTG-30/50-TGGTGTGTAGT
TCTGCCAATCA-30 (Yamamoto et al., 2006). The cellular GAPDH DNA
was amplified with primer pair 50-ATCATCCCTGCCTCTACTGG-30/50-
GTCAGGTCCACCACTGACAC-30, and the results were used to normalize
the amounts of viral DNA. Real-time PCR was conducted with the LightCycler
FastStart DNA Master SYBR Green 1 System (Roche) in accordance with the
manufacturer’s instructions.
Identification of Escape Mutations
Wild-type HIV-1NL4-3 was grown in MxB-expressing SupT1 cells until severe
cytopathology and a high level of virus production were observed. The newly
produced viruses were used to reinfect fresh MxB-expressing SupT1 cells to
select for resistant viruses. After five such passages, viruses were able to repli-
cate as well in MxB-expressing SupT1 cells as in the control SupT1 cells. As a
control, we also grew the wild-type HIV-1NL4-3 in the control SupT1 cells for the
same number of passages to identify spontaneous mutations. Viral RNA was
extracted from viruses of various passages and amplified by RT-PCR using
five pairs of primers that cover the entire viral genome. The PCR products
were directly sequenced at McGill University and Genome Quebec Innovation
Center. The results were aligned to the sequence of parental HIV-1NL4-3 pro-
viral DNA.408 Cell Host & Microbe 14, 398–410, October 16, 2013 ª2013 ElsevSUPPLEMENTAL INFORMATION
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